Regarding MHC expression, while BRAF-mutant melanoma cell lines had an increase in surface MHC-I, it decreased in BRAF-WT cells after vemurafenib treatment [in line with (Frazao et al., 2017; López-Cobo et al., 2017)] and this decrease was maintained when both drugs were combined. The gene discussed is HLA-C; the disease is melanoma.